Amphastar Pharmaceuticals (AMPH) Competitors

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.

Does the MarketBeat Community favor AMPH or NUVL?

Amphastar Pharmaceuticals received 347 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.95% of users gave Nuvalent an outperform vote while only 65.88% of users gave Amphastar Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amphastar Pharmaceuticals	Outperform Votes 392 65.88%	Underperform Votes 203 34.12%
Nuvalent	Outperform Votes 45 78.95%	Underperform Votes 12 21.05%

Which has more volatility and risk, AMPH or NUVL?

Amphastar Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Do insiders & institutionals believe in AMPH or NUVL?

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, AMPH or NUVL?

Amphastar Pharmaceuticals has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$731.97M	1.53	$137.54M	$3.06	7.68
Nuvalent	N/A	N/A	-$126.22M	-$3.90	-18.15

Do analysts rate AMPH or NUVL?

Amphastar Pharmaceuticals currently has a consensus price target of $43.50, suggesting a potential upside of 85.11%. Nuvalent has a consensus price target of $113.44, suggesting a potential upside of 60.28%. Given Amphastar Pharmaceuticals' higher probable upside, equities analysts plainly believe Amphastar Pharmaceuticals is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Is AMPH or NUVL more profitable?

Amphastar Pharmaceuticals has a net margin of 21.80% compared to Nuvalent's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	21.80%	26.44%	11.89%
Nuvalent	N/A	-28.63%	-27.15%

Does the media favor AMPH or NUVL?

In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Amphastar Pharmaceuticals and 6 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.22 beat Amphastar Pharmaceuticals' score of 1.13 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Amphastar Pharmaceuticals beats Nuvalent on 11 of the 18 factors compared between the two stocks.